CEO calls it an ‘important day for women’s health.’ Wall Street appears unimpressed
This Peninsula company reported strong results from a late-stage clinical trial of its experimental treatment for women who suffer from heavy bleeding and pain due to uterine fibroids. But potential competition from a biopharma giant may be keeping investor enthusiasm in check.